HOMEPAGE
Fully Diluted Subscribe

NYSE · Biotech stocks database

RCUS — Arcus Biosciences Inc.

RCUS (Arcus Biosciences Inc.) stock: $18.28, $2.63B market cap, $694.0M cash, $2.04B EV, $2.40B fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.

Source: 10-K FY2025 via SEC EDGAR

Share price
$18.28
Market cap
$2,632.1M
Cash
$694.0M
Enterprise value
$2,040.1M

Balance sheet

Cash$694.0M
Debt$102.0M
Net cash$592.0M
Enterprise value$2,040.1M
Basic shares127.3M shares
Fully diluted shares131.4M shares
Fully diluted market cap$2,402.6M
Cash per share$5.45
Quarterly burn$119.0M
Cash runway6.5 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common
127.3M
Pre-funded warrants
0.0M
Options
—
RSUs
—
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
4.1M
FDSO
131.4M

Cap table as of 2026-07-30.

Price history

Loading RCUS daily closes…

Loading price history…

Next catalyst

casdatifan · Est. Nov 15, 2026 · quarter midpoint · guided Now

Recently reported

casdatifan Phase 1/2 Positive · 2026-10-20
ARC-20 · clear cell renal cell carcinoma (ccRCC)
Primary: Efficacy (confirmed objective response rate, progression-free survival, overall survival) across ARC-20 cohorts of casdatifan alone or in combination in clear cell renal cell carcinoma; data cut-off September 4, 2026 — First-line casdatifan + zimberelimab (n=30): landmark PFS 86% at 6 months and 69% at 12 months, cORR 50%, primary progression 6.7%. Second-line casdatifan + cabozantinib (n=43): median PFS 14.5 months, 18-month landmark OS 77%, cORR 44%. Late-line casdatifan monotherapy pooled (n=121): median OS 35 months, median PFS 13 months, cORR 36%
· First-line casdatifan + ipilimumab + zimberelimab: primary progression in only one patient (4%, n=24 with at least one scan; n=31 dosed)
· Second-line combination efficacy was similar in patients who had progressed on a prior TKI (approximately 60% of 2L patients)
· Late-line monotherapy patients were heavily pre-treated: 52% had received at least three prior lines of therapy
· Median follow-up: 11.5 months (1L casdatifan + zimberelimab), 21.3 months (2L combination), 28 months (late-line monotherapy)
Safety: No unexpected safety signals were observed in any cohort; casdatifan monotherapy showed acceptable and manageable adverse events across all doses
Source release →
Zimberelimab Phase 3 Mixed · 2026-10-20
ARC-20
Primary: ARC-20 platform study data update for casdatifan combinations in clear cell renal cell carcinoma (data cut-off September 4, 2026) — First-line casdatifan + zimberelimab (n=30, 11.5 months median follow-up): confirmed objective response rate (cORR) 50%, landmark PFS 86% at 6 months and 69% at 12 months, primary progression 6.7% (n=2)
· First-line casdatifan + ipilimumab + zimberelimab: one patient with primary progression (4%, n=24 with at least one scan; n=31 dosed), 3 months median follow-up
· Second-line casdatifan + cabozantinib (n=43, 21.3 months median follow-up): median PFS 14.5 months, 18-month landmark overall survival 77%, cORR 44%
· Late-line casdatifan monotherapy (n=121 pooled): median overall survival 35 months, median PFS 13 months, cORR 36%
· Phase 3 PEAK-1 (2L casdatifan + cabozantinib) enrolling; first-line Phase 3 PEAK-20 on track to start by year-end 2026
Safety: No unexpected safety signals in any cohort; monotherapy adverse events described as acceptable and manageable across doses
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego